2. Science & Technology Collaboration with China

3. Flexible approach to technology transfer and IP licensing – Easy Access Research and Easy Access IP

4. Mass Innovation &
Mass Entrepreneurship
UNSW is championing a new government backed bilateral $100 million initiative to drive innovation, entrepreneurship and engagement between Australia and China
Ambitious, government-backed initiative bringing the successful Chinese ecosystem to Australia

5. Cover option 1
The vision was endorsed by Australian Prime Minister and Chinese Premier at the Great Hall of the People on 14th April 2016

6. 146 A$72 billion R&D budget Mass Innovation & Mass Entrepreneurship
Torch is…
1988
146
high tech zones and science
parks
Hundreds of thousands of companies
A$72 billion R&D budget
11% China's GDP
World leading tech platform
Cover option 1
Mass Innovation &
Mass Entrepreneurship

7. Mass Entrepreneurship
The first Torch precinct
outside China
Cover option 1
Mass Innovation &
Mass Entrepreneurship

8. Why are we doing this? UNSW 2025 Strategy Why are we doing this?

9. UNSW Innovation Precinct:
2025 Strategy
Theme B3: Knowledge exchange for social progress and economic prosperity
To establish UNSW as a world-leading university for industry engagement
To have an effective industry-staff-student ecosystem for innovation and entrepreneurship
To forge global alliances to ensure knowledge exchange contributes across the world
UNSW Innovation Precinct:
We will establish a ground-breaking and internationally connected UNSW Innovation Precinct which will bring together industry, SMEs, entrepreneurs, investors and policy makers from around the world to our campus.
To establish UNSW as a world-leading university for industry engagement
To have an effective industry-staff-student ecosystem for innovation and entrepreneurship
To forge global alliances to ensure knowledge exchange contributes across the world

10. Two sites near UNSW currently under consideration
Ten Year Blueprint
for Innovation
By 2020, we will have created a new state-of-the-art 20,000 sqm innovation precinct
By 2020, we will have created a new state-of-the-art 20,000 sqm innovation precinct
We have partnered with China's TusHoldings to develop a Feasibility Study to scope the Phase Two site
Two sites near UNSW currently under consideration

11. UNSW’s Chinese Industry Partners
A Snapshot “
UNSW has great strengths in education and research. It is a key participant in the Sino-Australian bilateral research relationship and is an important contributor to many collaborative projects between the two countries. “
– Liu Yandong

12. ~55% of Emerging Market growth will be driven by Asia
Pharmerging Markets in Asia for 2016
APAC Market Potential Assessment*
*For countries with >10Mn population
*Values in USD Billion
Asian Pharma emerging Markets will add ~USD 97Bn in annualised market value by 2016, of which
~75% would be attributable to China alone

13. Top 10 Therapeutic Areas per APAC Country, MAT Q2 2012
Despite the heterogeneous market environment, most Asian countries share the same top indications
Top 10 Therapeutic Areas per APAC Country, MAT Q2 2012
Rank
South Korea
ANZ
Japan
China+HK
Taiwan
India
Singapore
Thailand
Philippines
Malaysia
Vietnam*
Indonesia* 1
NSCLC
Hepatitis C
Diabetes Mellitus Type 2
HIV
Psoriasis, Various
Hypertension 2
Asthma
COPD
Breast Cancer
Schizophrenia
Prediabetic 3
Psoriasis
Congenital Bleeding Disorder
Rheumatoid Arthritis
Leukemia 4
Nasopharyn-geal Carcinoma
Solid Tumors
Epilepsy, Partial Seizures
Influenza 5
Crohn's Disease
Cancer
Fasting State
Urinary Bladder, Overactive
Cushing's Disease
Colorectal Neoplasms 6
Colorectal Cancer, Various
Depression
Complicated Intra-Abdominal Infection
Prostate Cancer
Dyslipidemia 7
Gout
Lung Cancer
Advanced Solid Tumors
Cardiovascu-lar Disease
Lupus, Various
Prostatic Hyperplasia 8
Metastatic Breast Cancer
Hypercholes-terolemia
Community-Acquired Bacterial Pneumonia 9
Gastric Cancer
Crohn’s Disease
Major Depressive Disorder
Gastric Cancer, Various
Contraception
Subfertility 10
Ulcerative Colitis
Gastric Ulcers
Hepatitis B
Critical Limb Ischemia
Metastatic Colorectal Cancer
Multiple Sclerosis
Ascaris Lumbricoides
The Top 2 TAs are well-represented indications in each APAC country: - Oncology & Immunology: Top indications include Breast Cancer, autoimmune diseases (i.e. Rheumatoid Arthritis, Crohn’s Disease) - Endocrine: Top indication is Diabetes Mellitus Type 2
Increasing affluence in Asia has led to: - Increased prevalence of lifestyle diseases such Diabetes Mellitus Type 2 and COPD - Better patient affordability and patient education level to seek treatment for diseases such as Rheumatoid Arthritis and Schizophrenia
* There are less than 10 clinical trials with listed indications for Indonesia in MAT Q2 2012

15. SCR Overview
First purpose built, publicly funded early phase clinical trial facility in NSW
Core Infrastructure Facility supporting “First Time in Human” and “First Time in Patient” Clinical Trials- a strategic investment for UNSW and the NSW Government
Aligned to the UNSW “Blueprint to Beyond”, the UNSW Strategic Intent paper, and the implementation of the NSW Government Health and Medical Research Strategic Review
SCR has been funded by:
UNSW
NSW Government
Commonwealth Government
Bench to Bedside becomes a reality “in-house” and SCR is the State centre for NSW

16. SCR Overview
Scientia Clinical Research Limited - Company limited by Guarantee
Not for Profit
SCR Board
40 year lease of 2 floors of Bright Building (5&6)
Service Agreement with Prince of Wales Hospital /SESLHD
Own legal entity to enable timely negotiations, contracts , choice of Ethics Committee etc.
Commencement of operations Q1/2 2017

17. Creating a Research Hub
Co-located in a major research precinct with UNSW and the Lowy Cancer Research Centre as well as Prince of Wales Hospital, Royal Hospital for Women and Sydney Children’s Hospital
Enhancing the skills and knowledge of clinical researchers and ancillary staff
Attracting and retaining high quality clinical researchers in Australia
Supporting better outcomes for patients by improving clinical standards
Providing more opportunities for patients to be included in clinical trials
Creating career opportunities for staff wanting to specialise in clinical research
Establishing a support network for researchers to increase trial activity and share ideas
Increasing research revenue to support local research

18. Australian Early Phase Facilities
Unit
Owner
City
Bed capacity
Clinical Trial Mix
Nucleus Network
BakerIDI
Melbourne 80
85% HV % patient
Linear Clinical Research
Perkins Institute
Perth
30 (45)
70% HV % patient
Q-Pharm
QIMR
Brisbane 46
90% HV % patient
CMax
I’ROM
Adelaide 50
Scientia
UNSW
Sydney 30

19. The SCR Team Lisa Nelson, CEO Charlotte Lemech, Medical Director
Extensive phase I experience and clinical trial expertise, both local and international including the design, establishment and running of Scientia, Nucleus Network and Linear Clinical Research
Charlotte Lemech, Medical Director
Medical Oncologist and investigator in over 30 oncology and haematology studies including first-in-patient studies in the UK and Australia, with an interest in genitourinary cancers and immunotherapy
Franziska Loehrer, Quality Systems & Compliance Manager
Extensive phase I experience, including the General Manager of the phase I GSK unit, established a consultancy business providing clinical trial QA, compliance, study operations and training services
Peter Hodsman, Deputy Medical Director
General Physician with over 30 years clinical trial experience in academia, and big pharmaceutical and biotechnology companies. PI in more than 200 Phase 1 clinical trials, including more than 50 FTIH
Michael Araco, Consultant PI/CI
Medical Practitioner with extensive early phase experience. CI/PI in approximately 250 studies including over 50 first in man studies

20. The SCR Network
Our referral network is within the South Eastern Sydney Local Health District and affiliated with a major research precinct with UNSW, POWH and SCH.
We will recruit patients from across Sydney and NSW to our clinical trials.

21. The Facility
First-in-human, first-in-patient clinical trials in healthy volunteers and patient groups
Ability to perform and support later phase trials in patient groups across therapeutic disciplines
Level 5
17 consult rooms
2 procedure rooms
Board room and offices
IP dispensing suite

23. Ambulatory telemetry, blood pressure and holter monitoring, spirometry
Level 6
30 inpatient beds
2- and 4-bed private rooms
24-bed open ward
Laboratory and freezer room
IP suite
Ambulatory telemetry, blood pressure and holter monitoring, spirometry

24. Laboratory capabilities
Pharmacy services
Grade D manufacturing suite
Temperature monitored storage and facility for aseptic reconstitution, cytotoxic admixing, blinded packaging
Laboratory capabilities
Receipt, distribution of samples
Freezer room
LCMS assay development and processing
Quantitation of peptides and small molecules

27. Trial One Automates clinic operations manage recruitment
real-time study data collection to reduce errors and timelines
sample tracking
data management and reporting
Integrates with bedside patient monitoring, telemetry, ECGs
Supports open-label, single and double blinding
Generates schedules and provides appointment reminder notifications
Allows remote monitoring
Tablet-compatible

28. Lisa Nelson CEO Mobile: 0438 008 816 Email: lisa.nelson@unsw.edu.au